Jin Zeyi, Yan Bing, Zhang Luo, Wang Chengshuo
Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of Nasal Diseases, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China.
Expert Rev Clin Immunol. 2025 Apr;21(4):473-492. doi: 10.1080/1744666X.2025.2459929. Epub 2025 Jan 31.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease. High proportions of patients with CRSwNP characterized by type 2 inflammation fail to gain adequate control with conventional treatment. The application of biologics in clinics and assessments of novel biologics in clinical trials are blooming in expectations to fulfill the unmet medical needs of patients with CRSwNP with type 2 inflammation.
After an extensive search of PubMed, Medline, and EMBASE for the most recent evidence, we thoroughly summarize current advances in biological therapies for treating patients with CRSwNP.
In recent years, biological therapy has been in the spotlight in clinical studies on CRSwNP. Biologics have proven to be efficacious in reducing nasal polyp size, alleviating CRSwNP-related symptoms, improving quality of life, and reducing the need for systemic corticosteroids or endoscopic sinus surgery for nasal polyps. The considerable efficacy and safety profile of biologics has offered patients with refractory CRSwNP another treatment option. However, some concerns remain to be addressed. Aspects such as the position of biological therapy in the management of CRSwNP, traits of patients suitable for certain biologics, etc. necessitate efforts to elucidate these unknowns in order to provide patients with tailored therapy.
伴鼻息肉的慢性鼻-鼻窦炎（CRSwNP）是一种异质性疾病。以2型炎症为特征的CRSwNP患者中，很大比例的患者采用传统治疗无法获得充分控制。生物制剂在临床上的应用以及新型生物制剂在临床试验中的评估正在蓬勃发展，以期满足2型炎症CRSwNP患者未得到满足的医疗需求。
在对PubMed、Medline和EMBASE进行广泛检索以获取最新证据后，我们全面总结了治疗CRSwNP患者的生物治疗的当前进展。
近年来，生物治疗在CRSwNP的临床研究中备受关注。生物制剂已被证明在缩小鼻息肉大小、减轻CRSwNP相关症状、改善生活质量以及减少鼻息肉全身用糖皮质激素或内镜鼻窦手术需求方面有效。生物制剂可观的疗效和安全性为难治性CRSwNP患者提供了另一种治疗选择。然而，一些问题仍有待解决。生物治疗在CRSwNP管理中的地位、适合某些生物制剂的患者特征等方面需要努力阐明这些未知因素，以便为患者提供量身定制的治疗。
